Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that ethanol extract of Syzygium aromaticum (clove) leaves significantly improved lipid profiles and increased body weight in testosterone-induced benign prostatic hyperplasia rats, suggesting potential anti-hyperlipidemic effects and modulation of body weight through metabolic activity.

The authors concluded that while finasteride 1 mg affects prostate-related pathways, evidence is insufficient to prove clinical benefits for prostate outcomes compared to the established effectiveness of finasteride 5 mg.

This review reported that while finasteride is effective for treating androgenetic alopecia and benign prostatic hyperplasia, it may cause adverse effects such as sexual dysfunction and psychological symptoms, which require careful patient education and management to ensure treatment adherence and satisfaction.

In this study, researchers found that fenugreek seed extract reduced prostate size, DHT levels, and cell proliferation in a testosterone-induced BPH rat model while modulating various genetic expressions, suggesting its potential as an alternative treatment for benign prostatic hyperplasia.

Plant-based treatments may help reduce BPH symptoms, but more research is needed.

In this retrospective cohort study, researchers found no significant difference between finasteride and dutasteride in terms of reducing prostate volume or adverse effects among patients with benign prostatic hyperplasia, although both drugs improved lower urinary tract symptoms over one year by reducing prostate volume.

This article critiques a study on finasteride use among individuals with benign prostatic hyperplasia and androgenetic alopecia, highlighting the flawed methodology and potential confounding effects of hair loss on mental health, which confuses interpretation of psychiatric risk.

This study found that among patients over 45 with lower urinary tract symptoms due to benign prostatic hyperplasia, those with androgenic alopecia had worse symptoms and higher testosterone levels than those without baldness.

This study found that finasteride users had a very low rate of psychiatric side effects, with no significant increase in BPH patients and a slight increase in anxiety and depression among AGA patients.

This study found no significant association between male pattern baldness and benign prostatic hyperplasia.

The researchers reported that finasteride was effective in controlling hormone-related dysfunction in an adult dog diagnosed with benign prostatic hyperplasia, although the condition regressed after the medication was withdrawn.

This study observed that adherence to finasteride treatment in patients with benign prostatic hyperplasia at a clinic in Tepic Nayarit had not been previously evaluated in Mexico.

Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.

This study found that the combination of finasteride and doxazosina was more effective in reducing the long-term progression of benign prostatic hyperplasia compared to monotherapy.

This study concluded that androgenetic alopecia was not a prognostic indicator for COVID-19, but hospitalization frequency increased in older patients with benign prostatic hyperplasia, supporting an androgen-mediated severity hypothesis.

This study reports that comorbidities and anti-androgen therapy were associated with lower SARS-CoV-2 vaccination rates among patients with androgenetic alopecia, emphasizing the need to promote vaccination within this group.

This study observed no association between androgenetic alopecia and benign prostatic hyperplasia in men aged 20 and older, although a positive family history was linked to early onset of hair loss.

This study found that men with benign prostate hyperplasia showed increased meibomian gland dysfunction and tear film instability compared to age-matched controls, and were also more likely to have androgenic alopecia.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

This review discusses the etio-pathogenetic factors in benign prostatic hyperplasia and their role in the development of lower urinary tract symptoms but reports no new research findings.

This review discusses hormonal control and treatment options for benign prostatic hyperplasia, highlighting similar efficacy and safety between finasteride and dutasteride, and reports no clinical results; further studies are suggested for new therapeutic agents.

This article discusses advancements and future directions in the treatment of benign prostatic hyperplasia, highlighting ongoing clinical trials of novel techniques, but it reports no new clinical results.

This review discusses the potential risks of ejaculatory dysfunction associated with both medical and surgical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and their implications for male fertility, but it reports no new clinical results.

Finasteride is effective for hair loss and may help prevent prostate cancer without increasing high-grade cancer risk.

This review details contemporary medical management options for benign prostatic hyperplasia, highlighting the expanding role of phosphodiesterase-5 inhibitors and beta-3 agonists, but reports no new clinical findings.

Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.

This study found that among men with Benign Prostatic Hyperplasia, treatment with the 5α-reductase inhibitor finasteride for three months significantly reduced levels of dihydrotestosterone and estradiol, hormones involved in prostate enlargement, without altering follicle-stimulating hormone or luteinizing hormone levels.

The authors discuss BPH treatment options and highlight that while medications can manage symptoms, recent minimally invasive procedures may offer promise for elderly males who are not surgical candidates or wish to avoid surgery.

This article updates on the medical management of benign prostatic hyperplasia in companion animals and reports no new clinical findings; the authors discuss existing treatments.